Product Name
CHMP4B, siRNA
Full Product Name
CHMP4B siRNA (Mouse)
Product Synonym Names
Charged multivesicular body protein 4b; Chromatin-modifying protein 4b; CHMP4b
Product Gene Name
CHMP4B sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9D8B3
Specificity
CHMP4B siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CHMP4B gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CHMP4B sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CHMP4B sirna
siRNA to inhibit CHMP4B expression using RNA interference
Applications Tested/Suitable for CHMP4B sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CHMP4B. It may not necessarily be applicable to this product.
NCBI Accession #
NP_083638.1
[Other Products]
NCBI GenBank Nucleotide #
NM_029362.3
[Other Products]
UniProt Primary Accession #
Q9D8B3
[Other Products]
UniProt Secondary Accession #
Q3TXM7; Q91VM7; Q922P1; A2AVM1[Other Products]
UniProt Related Accession #
Q9D8B3[Other Products]
Molecular Weight
24,936 Da
NCBI Official Full Name
charged multivesicular body protein 4b
NCBI Official Synonym Full Names
charged multivesicular body protein 4B
NCBI Official Symbol
Chmp4b??[Similar Products]
NCBI Official Synonym Symbols
C76846; Snf7-2; 2010012F05Rik
??[Similar Products]
NCBI Protein Information
charged multivesicular body protein 4b
UniProt Protein Name
Charged multivesicular body protein 4b
UniProt Synonym Protein Names
Chromatin-modifying protein 4b; CHMP4b
Protein Family
Charged multivesicular body protein
UniProt Gene Name
Chmp4b??[Similar Products]
UniProt Synonym Gene Names
CHMP4b??[Similar Products]
UniProt Entry Name
CHM4B_MOUSE
UniProt Comments for CHMP4B
CHMP4B: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. When overexpressed, membrane-assembled circular arrays of CHMP4B filaments can promote or stabilize negative curvature and outward budding. Via its interaction with PDCD6IP involved in HIV-1 p6- and p9-dependent virus release. Defects in CHMP4B are the cause of cataract posterior polar type 3 (CTPP3). A subcapsular opacity, usually disk-shaped, located at the back of the lens. It can have a marked effect on visual acuity. Belongs to the SNF7 family.
Protein type: Membrane protein, peripheral
Cellular Component: internal side of plasma membrane; membrane coat; membrane; cytoplasm; midbody; nucleus; endosome
Molecular Function: identical protein binding; protein homodimerization activity
Biological Process: protein transport; cell separation during cytokinesis; transport; vacuolar transport; non-lytic virus budding; regulation of viral reproduction; posttranslational protein targeting to membrane; mitotic metaphase plate congression; protein homooligomerization; nuclear organization and biogenesis
Research Articles on CHMP4B
1. CHMP4B, through its association with chromatin, may participate in the autophagolysosomal degradation of micronuclei and other extranuclear chromatin.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
